Diligence memo · auto-generated · as of July 2, 2026
Cytimmune Sciences Inc
Cytimmune Sciences Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Cytimmune Sciences Inc operates in Biotechnology, based in ROCKVILLE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Cytimmune Sciences Inc has raised $9.3M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.4M on 2014-03-31.
Most recent recorded round closed around 2020-12-10.
Valuation (modeled)modeled
Provath models Cytimmune Sciences Inc at approximately $29M (range $1.1M–$143M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.16× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 19 months.
Last raise 5.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 9.9× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 55% of Biotechnology peers (4293 compared).
Modeled value ranks above 35% of those peers.
Closest niche peers: TRACT Therapeutics, Inc., TechAccel, LLC, Arrakis Therapeutics, Inc., Trident Labs, Inc., Meissa Vaccines Inc.
Peoplefiled
20 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.